Remember when mutations were purely the domain of genetics technologies? It is 2024 and those days should be as dead in your mind as the f'ing western blot. (Which....isn't entirely dead....and, I have to admit has it's place sometimes because making targeted assays for ultralow abundance stuff can be a drag)
It would be fair to argue that their sample input is large (>500mg) but they obviously only used a fraction of a percent for each run. Probably also fair to argue that 60 min is a long LCMS experiment, but just check out how great that data looks! They ran at 600nL/min which is easy to maintain and tuning in the FAIMS cleans up the background and overall data quality to a really impressive extent.
In the era of targeted small molecule inhibitors (and - probably more importantly - KRAS epitope targeted mABs) knowing the mutation that is actually present - and where - couldn't be more important for patients. And they show they can clearly resolve ALL the main mutations.
Incredible work I couldn't recommend more.
No comments:
Post a Comment